Literature DB >> 22098854

Gene expression profiling in breast cancer: classification, prognostication, and prediction.

Jorge S Reis-Filho1, Lajos Pusztai.   

Abstract

Microarray-based gene expression profiling has had a major effect on our understanding of breast cancer. Breast cancer is now perceived as a heterogeneous group of different diseases characterised by distinct molecular aberrations, rather than one disease with varying histological features and clinical behaviour. Gene expression profiling studies have shown that oestrogen-receptor (ER)-positive and ER-negative breast cancers are distinct diseases at the transcriptomic level, that additional molecular subtypes might exist within these groups, and that the prognosis of patients with ER-positive disease is largely determined by the expression of proliferation-related genes. On the basis of these principles, a molecular classification system and prognostic multigene classifiers based on microarrays or derivative technologies have been developed and are being tested in randomised clinical trials and incorporated into clinical practice. In this review, we focus on the conceptual effect and potential clinical use of the molecular classification of breast cancer, and discuss prognostic and predictive multigene predictors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22098854     DOI: 10.1016/S0140-6736(11)61539-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  270 in total

1.  Candidate early detection protein biomarkers for ER+/PR+ invasive ductal breast carcinoma identified using pre-clinical plasma from the WHI observational study.

Authors:  Matthew F Buas; Jung-hyun Rho; Xiaoyu Chai; Yuzheng Zhang; Paul D Lampe; Christopher I Li
Journal:  Breast Cancer Res Treat       Date:  2015-08-30       Impact factor: 4.872

2.  In stage II/III lymph node-positive breast cancer patients less than 55 years of age, keratin 8 expression in lymph node metastases but not in the primary tumour is an indicator of better survival.

Authors:  Serena Bonin; Danae Pracella; Renzo Barbazza; Sandro Sulfaro; Giorgio Stanta
Journal:  Virchows Arch       Date:  2015-02-28       Impact factor: 4.064

Review 3.  Tumor heterogeneity and its implication for drug delivery.

Authors:  Tracy A Denison; You Han Bae
Journal:  J Control Release       Date:  2012-04-15       Impact factor: 9.776

4.  Omnibus risk assessment via accelerated failure time kernel machine modeling.

Authors:  Jennifer A Sinnott; Tianxi Cai
Journal:  Biometrics       Date:  2013-11-06       Impact factor: 2.571

5.  The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma.

Authors:  Rocío Montes de Oca; Zachary A Gurard-Levin; Frédérique Berger; Haniya Rehman; Elise Martel; Armelle Corpet; Leanne de Koning; Isabelle Vassias; Laurence O W Wilson; Didier Meseure; Fabien Reyal; Alexia Savignoni; Bernard Asselain; Xavier Sastre-Garau; Geneviève Almouzni
Journal:  Mol Oncol       Date:  2014-11-20       Impact factor: 6.603

Review 6.  High-throughput gene expression and mutation profiling: current methods and future perspectives.

Authors:  Thomas Karn
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

7.  Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers.

Authors:  N Sänger; K Engels; A Graf; E Ruckhäberle; K E Effenberger; T Fehm; U Holtrich; S Becker; T Karn
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-11       Impact factor: 2.915

8.  Pathway-based analysis of breast cancer.

Authors:  Dong Song; Miao Cui; Gang Zhao; Zhimin Fan; Katherine Nolan; Ying Yang; Peng Lee; Fei Ye; David Y Zhang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

Review 9.  The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.

Authors:  Kivilcim Ozturk; Michelle Dow; Daniel E Carlin; Rafael Bejar; Hannah Carter
Journal:  J Mol Biol       Date:  2018-06-15       Impact factor: 5.469

10.  Chromatin Regulators as a Guide for Cancer Treatment Choice.

Authors:  Zachary A Gurard-Levin; Laurence O W Wilson; Vera Pancaldi; Sophie Postel-Vinay; Fabricio G Sousa; Cecile Reyes; Elisabetta Marangoni; David Gentien; Alfonso Valencia; Yves Pommier; Paul Cottu; Geneviève Almouzni
Journal:  Mol Cancer Ther       Date:  2016-05-16       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.